Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -501.93% |
| Mar 31, 2026 | 30.34% |
| Dec 31, 2025 | -40.37% |
| Sep 30, 2025 | 34.48% |
| Jun 30, 2025 | 10.59% |
| Mar 31, 2025 | -8.77% |
| Dec 31, 2024 | 176.13% |
| Sep 30, 2024 | -66.41% |
| Jun 30, 2024 | 161.18% |
| Mar 31, 2024 | -368.11% |
| Dec 31, 2023 | -38.54% |
| Sep 30, 2023 | 57.54% |
| Jun 30, 2023 | -2.35% |
| Mar 31, 2023 | -24.79% |
| Dec 31, 2022 | -20.09% |
| Sep 30, 2022 | 39.82% |
| Jun 30, 2022 | 929.95% |
| Mar 31, 2022 | -79.04% |
| Dec 31, 2021 | -75.53% |
| Sep 30, 2021 | 71.06% |